RegCell is a preclinical-stage biotechnology company focused on utilizing regulatory T-cell reprogramming platforms to develop cell therapies for autoimmune diseases. The company is headquartered in Japan.
Subscribe to see RegCell’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
RegCell is a biotech company headquartered in Japan. It has raised at least $111.8M across the 3 funding rounds on record. Its most recent funding round, Series A, raised $66M in September 2026. Xcout tracks 3 named people at RegCell, including Michael McCullar (president and CEO).
As of 17 November 2026. Source: Xcout Intel.
At least $111.8M raised across the 3 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $66M | 18 named | |
| Seed | $8.5M | — | |
| Grant | $37.3M | 2 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A funding-flow diagram of the 18 named investors across 2 rounds: who backed which round, who led it, and who came back for the next one.
Sign in to see it, or subscribe for the full funding history →
A few of RegCell's closest competitors — see the full list of competitors and alternatives →
GentiBio is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, with an additional office in Seattle, Washington, developing engineered regulatory T cell (Treg) therapies to cure Type 1 diabetes and other autoimmune diseases.
Egle Therapeutics SAS is a clinical-stage biotechnology company headquartered in Paris, France, that develops precision medicines designed to modulate regulatory T cells.
Slate Bio, Inc. is a privately held pre-clinical stage biotechnology company founded in 2020 and headquartered in Charlottesville, Virginia, specializing in T regulatory therapies to address autoimmune diseases.
TRex Bio, Inc. is a clinical-stage biotechnology company headquartered in South San Francisco, California. The company focuses on discovering and developing precision therapeutics to treat moderate-to-severe immune-mediated diseases by targeting regulatory T cells.
Tr1X is a private, clinical-stage biotechnology company focused on developing regulatory T cell-based products for autoimmune and inflammatory diseases. The company aims to advance Tr1-based immunotherapies to address unmet medical needs and is headquartered in San Diego, California.
TeraImmune, Inc. is a U.S. biotechnology company developing cell-based immunotherapies intended to restore immune tolerance. Its work is aimed primarily at patients with autoimmune diseases and potentially transplant-related immune disorders.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about RegCell? Suggest a correction · Work at RegCell? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.